Raptor Pharmaceutical Corp.  

(Public, NASDAQ:RPTP)   Watch this stock  
Find more results for William D. Keltner
12.68
-0.32 (-2.46%)
Sep 3 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 12.64 - 13.30
52 week 7.85 - 16.28
Open 13.16
Vol / Avg. 895,445.00/1.07M
Mkt cap 1.06B
P/E     -
Div/yield     -
EPS -0.85
Shares 81.18M
Beta 0.30
Inst. own 66%
Nov 4, 2015
Q3 2015 Raptor Pharmaceutical Corp Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Sep 9, 2015
Raptor Pharmaceutical Corp at FBR Healthcare Conference Add to calendar
Aug 20, 2015
Raptor Pharmaceutical Corp Conference Call to discuss the Acquisition of Quinsair(TM)
Aug 6, 2015
Q2 2015 Raptor Pharmaceutical Corp Earnings Call
Aug 6, 2015
Q2 2015 Raptor Pharmaceutical Corp Earnings Release
Jun 24, 2015
Raptor Pharmaceutical Corp at JMP Securities Life Sciences Conference
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '15) 2014
Net profit margin -59.78% -75.60%
Operating margin -38.38% -57.63%
EBITD margin - -56.14%
Return on average assets -25.77% -35.29%
Return on average equity -72.30% -135.56%
Employees 123 -
CDP Score - -

Address

7 Hamilton Lndg Ste 100
NOVATO, CA 94949-8246
United States - Map
+1-415-4086200 (Phone)
+1-415-3828002 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Raptor Pharmaceutical Corp. is a biopharmaceutical company. The Company is focused on developing and commercializing transformative treatments for people affected by rare and debilitating diseases. The Company's product, PROCYSBI delayed-release capsules, received marketing approval from the FDA for the management of nephropathic cystinosis in adults and children six years and older. In Europe, PROCYSBI gastro-resistant hard capsules of cysteamine, received a marketing authorization from the EC, as an orphan medicinal product for the management of nephropathic cystinosis in the EU. Its pipeline includes its delayed-release form of cysteamine, or RP103 and its oral 4-methylpyrazole, or Convivia. It has product candidates in clinical development designed to potentially treat HD, NASH in children, Leigh syndrome and other mitochondrial disorders and ALDH2. Its preclinical programs are based upon bioengineered drug candidates that are designed to target cancer and other diseases.

Officers and directors

Llew Keltner Independent Chairman of the Board
Age: 65
Bio & Compensation  - Reuters
Julie Anne Smith President, Chief Executive Officer Designate, Director
Age: 44
Bio & Compensation  - Reuters
Michael P. Smith Chief Financial Officer
Age: 47
Bio & Compensation  - Reuters
Robert H. Uhl Managing Director
Bio & Compensation  - Reuters
Thomas E. Daley Chief Business Officer
Age: 52
Bio & Compensation  - Reuters
David A Happel Chief Commercial Officer
Age: 52
Bio & Compensation  - Reuters
Krishna R. Polu M.D. Chief Medical Officer
Age: 41
Bio & Compensation  - Reuters
Georges Gemayel Ph.D. Director
Age: 54
Bio & Compensation  - Reuters
Gregg A. Lapointe C.P.A. Director
Age: 56
Bio & Compensation  - Reuters
Christopher M. Starr Ph.D. Director
Age: 62
Bio & Compensation  - Reuters